GLP-1 Drugs Show Modest Weight Loss Benefit in PCOS — Evidence for Other Outcomes Remains Uncertain | Research

The takeaway

Meta-analysis of 11 RCTs found GLP-1 drugs reduce BMI by 1.38 kg/m² in PCOS women, but evidence for metabolic, reproductive, or psychological benefits remains low certainty.

-1.38 kg/m² BMI
Modest but significant weight reduction as add-on GLP-1 therapy in PCOS, though reproductive and metabolic benefits unproven

What the researchers found

GLP-1 RAs as add-on therapy reduced BMI by -1.38 kg/m² (95% CI -2.39 to -0.38; low certainty) in PCOS women. No significant differences for LDL, triglycerides. Insufficient evidence for glucose, insulin, hirsutism, menstrual regularity.

Why it matters

PCOS is the most common endocrine disorder in reproductive-age women. Understanding what GLP-1 drugs can and cannot do for PCOS guides clinical decision-making.

How the study worked

Systematic review and meta-analysis of 11 RCTs from Cochrane, EMBASE, and Medline (searched September 2024), registered in PROSPERO CRD42024535096.

What this study cannot tell us

Low certainty evidence overall. Most trials were short-term. No assessment of quality of life or reproductive outcomes in sufficient numbers. Heterogeneity in study designs.

How to read the evidence

Systematic review of RCTs with GRADE assessment. Low certainty evidence limits confidence in conclusions.

When this study was published

Published in 2025.

The bigger picture

Despite enormous enthusiasm for GLP-1 drugs, their proven benefits in PCOS are limited to modest weight loss. The field needs better-designed trials with PCOS-specific outcomes.

Questions still open

Would higher GLP-1 doses or newer agents (tirzepatide) show reproductive benefits in PCOS?
Should PCOS-specific clinical trials be designed with reproductive and hormonal primary endpoints?
Could combining GLP-1 drugs with metformin or OCP improve PCOS outcomes?

Common questions

Can GLP-1 drugs help with PCOS?

They can help with weight loss (about 1.4 kg/m² BMI reduction), but there is not yet enough evidence to know if they improve other PCOS symptoms like irregular periods, excess hair growth, or hormone levels.

Should women with PCOS take Ozempic?

GLP-1 drugs may be considered for weight management in PCOS with obesity, but they should not be expected to treat PCOS-specific symptoms based on current evidence. Better trials are needed.

Read the original research

GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis.

European journal of endocrinology

View on PubMed ↗Publisher’s paper ↗

Citation

Forslund, Maria; Wändell, Per; Forsberg, Lisa; Österberg, Marie; Dagerhamn, Jessica; Wernersson, Emma; Kärrman Fredriksson, Maja; Ringborg, Anna; Lindén Hirschberg, Angelica. (2026). GLP-1 receptor agonist treatment in women with polycystic ovary syndrome - a systematic review and meta-analysis.. European journal of endocrinology. https://doi.org/10.1093/ejendo/lvag033